Show Summary Details
Page of

Anthrax 

Anthrax

Chapter:
Anthrax
Author(s):

Arthur E. Brown

and Thira Sirisanthana

DOI:
10.1093/med/9780199204854.003.070620_update_003

July 30, 2015: This chapter has been re-evaluated and remains up-to-date. No changes have been necessary.

Update:

Description of ‘injection anthrax’, with discussion of the ongoing outbreak of this condition in Europe.

Updated on 27 Feb 2014. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 25 March 2017

Anthrax is primarily a disease of herbivorous mammals, caused by the Gram-positive rod Bacillus anthracis, which causes human infection when its spores enter the body, most commonly from handling infected animals or animal products. The disease occurs in most countries of the world, but not in those where the condition is controlled in livestock by vaccination programmes. Anthrax is a leading agent of biological warfare.

Pathophysiology—after entry into the body, anthrax spores are phagocytosed by macrophages and carried to regional lymph nodes, where they germinate to produce vegetative bacilli that enter the blood stream. These produce anthrax toxin, which has effects including impairment of cellular water homeostasis and of many intracellular signalling pathways.

Clinical features—anthrax occurs in three clinical forms based on the route of exposure. (1) Cutaneous—lesions are usually found on exposed areas of skin; a small papule develops at the site of infection, enlarges and ulcerates, with the painless ulcer becoming covered with a black leathery eschar surrounded by nonpitting oedema before healing in 2 to 6 weeks; associated systemic symptoms are usually mild. (2) Gastrointestinal—acquired by eating contaminated food and comprising (a) oropharyngeal anthrax, presenting with fever, neck swelling, sore throat, oropharyngeal ulcer, and dysphagia, OR (b) terminal ileal/caecal anthrax, presenting with fever, nausea, vomiting, and abdominal pain, followed by rapidly developing ascites and bloody diarrhoea. (3) Inhalation—aerosol exposure leads to a nonspecific viral-type prodrome which progresses to a fulminant stage of severe respiratory distress, cyanosis, stridor, and profuse sweating; up to half of patients develop anthrax meningitis; shock and death typically follow in hours or days. (4) Injection—acquired by injection of heroin contaminated with anthrax spores. Symptoms range widely, but usually include inflammation and oedema at the injection site (no eschar), which may be complicated by compartment syndrome, necrotizing fasciitis and sepsis.

Diagnosis—may be very difficult in the absence of a known outbreak, particularly for inhalation anthrax, where a clinical clue is widening of the mediastinum caused by lymphadenopathy. Confirmation is by laboratory identification of B. anthracis. Serological testing can be used for retrospective diagnosis.

Treatment—this is with supportive care and antibiotics, which are effective against the multiplying (vegetative) form of B. anthracis, but not against the spore form. Mild cases of cutaneous anthrax are usually treated with oral penicillin. For gastrointestinal, inhalational and meningeal anthrax, at least two antibiotics should be given intravenously, e.g. ciprofloxacin or doxycycline along with another antimicrobial expected to be effective (e.g. penicillin, ampicillin, rifampin, vancomycin, chloramphenicol, imipenem, clindamycin, and clarithromycin).

Prognosis—the mortality of untreated cutaneous anthrax is 10 to 20%, but fatalities are rare with appropriate antibiotic treatment. Almost all cases of inhalation anthrax and anthrax meningitis are fatal; initiation of treatment after the start of fulminant disease is rarely effective.

Prevention—routine immunization of livestock should be instituted in endemic areas with continuing cases of animal anthrax. Carcasses of animals suspected of dying from anthrax must be disposed of appropriately. Anthrax vaccines should be offered to members of high-risk groups, e.g. those at occupational risk, laboratory workers and some military groups. Postexposure prophylaxis should be given following suspected exposure to aerosolized anthrax spores (e.g. ciprofloxacin for 60 days).

The views expressed in this chapter are those of A E Brown and do not represent the positions of the United States Department of Defense or Army.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.